Niox Group plc, a UK-based medical device company, released its unaudited interim results for the six months ended June 30, 2024. The company reported strong financial performance with revenue growth of 12% (15% on a constant currency basis) to £21.0 million, up from £18.8 million in the same period last year. The clinical business revenue grew by 11% (14% on a constant currency basis) to £18.5 million. The companys adjusted EBITDA increased to £7.1 million, reflecting higher sales and a flat cost base, with an adjusted EBITDA margin of 33.8%. Niox Group plc also reported strong cash generation, with cash generated from operations of £6.0 million, and a strong balance sheet with no debt and cash of £21.5 million as of June 30, 2024. The company expanded its distributor network in the USA and EMEA, targeting areas of untapped potential. Niox Group plc also announced a tender offer to repurchase shares and return capital to shareholders. The companys outlook remains positive, with the board confident in achieving consensus expectations for the full year.
| Year | Revenue (£m) | Gross Margin | Total Expenditure (£m) | Adjusted EBITDA (£m) | Operating Profit (£m) | Profit Before Tax (£m) | Profit for the Financial Period (£m) | Cash at Period End (£m) |
|---|---|---|---|---|---|---|---|---|
| H1 2024 | 21.0 | 72% | 8.1 | 7.1 | 4.2 | 4.4 | 4.4 | 21.5 |
| H1 2023 | 18.8 | 73% | 7.5 | 6.2 | 3.0 | 2.9 | 3.4 | 23.8 |